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ABSTRACT 
 
Role of an Equine Homologue of Gonadotropin-Inhibiting Hormone in Controlling 
Secretion of Luteinizing Hormone in the Mare. (May 2012) 
 
Ligia Dias Prezotto, 
B.S., University of Sao Paulo, Pirassununga-SP-Brazil 
Co-Chairs of Advisory Committee: Dr. Gary L. Williams 
                 Dr. Marcel Amstalden 
 
Four experiments were conducted to test the hypothesis that RF-amide related 
peptide 3 (RFRP3) negatively regulate the secretion of LH in mares. In Exp. 1, mares 
received native gonadotropin-releasing hormone (GnRH) continuously at a rate of 20 
µg/h, delivered subcutaneously using Alzet osmotic pumps during the luteal phase of the 
estrous cycle. Mares were treated with i.v. bolus injections of 0, 500 and 1,000 µg 
eRFRP3 on days 4, 6 and 8 of cycle. Mean concentrations of LH in the peripheral 
circulation averaged 1.2±0.2 ng/mL and did not differ among groups before or following 
RFRP3 treatment. In Exp. 2, pituitary venous effluent was sampled for characterization 
of episodic release of LH. Mares received either saline or eRFRP3 (250 µg) i.v. every 10 
min for 6 h beginning 2 h after onset of sampling. At hour 6, each mare was challenged 
with 1 mg GnRH. Neither mean ICS concentrations of LH (1.3 ± 0.2 ng/ml), nor 
frequency (3.6 ± 0.55 episodes/h), amplitude (0.2 ± 0.03 ng/ml), or duration (36.3 ± 3.5 
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min) of individual secretory episodes, differed between groups before or after eRFRP3 
treatment. Area under the GnRH-induced LH curve (arbitrary units) also did not differ 
between control and RFRP3 treated mares (175.9 ± 11.4 vs. 192.6 ± 10.6). In Exp. 3, 
winter anovulatory mares (n=6) were treated continuously for 7 d with GnRH (100 µg/h) 
to stimulate synthesis of LH and increase circulating concentrations of LH to values 
similar to the breeding season. The ICS was catheterized for blood sampling and mares 
were treated with saline or RFRP3 (5 mg) in a replicated Latin square design. Treatment 
with RFRP3 failed to alter ICS mean concentration of LH (0.95 ± .03 ng/ml). Finally in 
Exp. 4, mares in the follicular phase of the estrous cycle were assigned randomly to 
receive either saline (n=3) or 10 µg/kg BW of oRFRP3 (n=3) in a single injection. No 
effect on mean concentration of LH was observed. In contrast to observations in birds 
and other mammals, results of the current experiments fail to provide evidence for 
functional activity of eRFRP3 or oRFRP3 in regulating LH release in the mare. 
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CHAPTER I 
INTRODUCTION 
 
 
 
The natural breeding season of the mare occurs during long days. Therefore, in 
the northern hemisphere, it is generally restricted to the interval between April and 
October. After this period, a majority of mares become anovulatory and ovaries remain 
quiescent throughout the winter. Most research in this area has focused on the roles of 
day-length [1], pineal melatonin [2], and gonadotropin releasing hormone (GnRH) 
secretion [3]. However, the neuroendocrine basis of equine reproductive seasonality has 
not been completely elucidated.  
The use of artificial lighting to extend day-length and hasten onset of spring 
transition is well-documented. It is an effective managerial strategy used by many large 
farms; however, the method is not widely utilized by smaller breeders because of 
limitations in facilities [4]. 
Pineal melatonin release, which increases in response to decreased photoperiod, 
has long been implicated in the control of seasonal reproduction through potential effects 
on secretion of GnRH [2]. There is some evidence that melatonin reduces GnRH content 
of the hypothalamus in mares [5] but a direct effect of melatonin on hypothalamic 
secretion of GnRH has not been demonstrated. Therefore, this area of investigation 
requires much additional work.  
 This thesis was written in the format and style of Domestic Animal Endocrinology. 
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Gonadotropin-releasing hormone is the primary regulator of both LH and FSH 
synthesis and secretion [6, 7, 8], and existing dogma indicates that the winter 
anovulatory state in mares is a consequence of reduced secretion of GnRH. Therefore, 
some studies have focused on pulsatile [9, 10] and continuous [9, 11, 12] administration 
of GnRH to induce follicular growth and ovulation in mares during the anovulatory 
state. Although, such treatments have clearly demonstrated their ability to stimulate 
ovarian activity successfully, studies conducted in our laboratory have questioned 
whether seasonal anovulation is controlled only by limitations of endogenous GnRH 
secretion, or involves changes in pituitary responsiveness. Using the intercavernous 
sinus (ICS) cannulation technique to measure secretion of GnRH, Cooper reported no 
change in GnRH release during 4 different seasons [13]. This observation would support 
the hypothesis that winter anovulation in the mare is mediated by changes in 
gonadotrope responsiveness. 
In 2000 Tsutsui et al. [14], reported the identification of a novel hypothalamic 
neuropeptide with a C-terminal LPLRF-amide sequence in the quail brain. This 
neuropeptide inhibited gonadotropin release in birds both in vivo and in cultured anterior 
pituitary cells. The functional RF-amide was named, gonadotropin-inhibiting hormone 
(GnIH). Although, other neuropeptide (e.g. endogenous opioid peptide (EOP) are known 
to project to the median eminence (ME) and to the posterior pituitary, and inhibit LH 
release by direct actions in the pituitary [15, 16], their physiological relevance regarding 
the control of gonadotropin release is controversial. Thus, GnIH became the most 
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physiologically relevant hypothalamic peptide shown to inhibit gonadotropin release in 
vertebrates and has been widely studied in this regard. 
Following its discovery in the avian brain, studies were conducted in other 
species, such as mammals, amphibians, and fish [17, 18, 19, 20, 21, 22]. These studies 
resulted in the finding of similar GnIH-related peptides broadly termed RF-amide related 
peptides (RFRP). All of these RFRP possess a LPXRF-amide sequence in the C-
terminus, similar to that observed in the avian GnIH [19, 23, 24, 25, 26, 27]. The RFRP 
gene encodes more than one peptide (i.e. RFRP1, RFRP2, and RFRP3). However, the 
RFRP3 appears to have the most potent effects on secretion of LH [19, 28].  
Initial work in birds focused on the possibility that the main effects of GnIH were 
at the hypothalamic level through effects on GnRH neurons [14, 17, 29, 30, 31]. 
However, studies in sheep were not able to confirm a decrease in GnRH concentrations 
in portal blood plasma after GnIH administration. Whereas, some investigators were able 
to report effects on GnRH expression in hypothalamic cells after giving RFRP3 through 
intracerebroventricular (ICV) injections [32], in vivo studies mainly measured dose-
related reductions in secretion of LH after injection of GnIH/RFRP3 [18, 20, 29, 33, 34, 
35].  
The potential role of RFRP3, the mammalian homolog of avian GnIH, in equine 
reproductive seasonality has not been elucidated. Because of the economic importance 
of the horse and its profound seasonality, it is essential that these studies be undertaken. 
The objectives of the studies described herein were to determine 1) whether eRFRP3 
have the ability to decrease mean concentrations of LH in peripheral plasma of mares in 
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the luteal phase of the estrous cycle during concomitant infusion of GnRH, 2) if 
continuous infusion of eRFRP3 has the ability to suppress the pulsatile release of LH in 
the intercavernous sinus (ICS) of mares during the follicular phase, 3) if eRFRP3 
injected into anovulatory mares treated continuously with GnRH (i.e. synthesis and 
release of LH is similar to what is observed during breeding season) results in a 
suppression of LH secretion, and 4) if ovine oRFRP3 injected into mares during the 
follicular phase suppresses LH secretion in the ICS. The overal hypothesis is that either 
eRFRP3 or oRFRP3 will disrupt the normal pattern of LH secretion as detected in the 
peripheral circulation or in the ICS effluent. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
 
 
2.1 Overview of reproduction in the mare 
Mares are seasonal long-day breeders with a natural breeding season extending 
on average from April to October in the Northern Hemisphere. Approximately 85% of 
mares become anovulatory during the late fall and winter. Resumption of ovarian cycles 
can occur as early as February or March and as late as May or June [1]. Around the time 
of the autumn equinox a reduction in synthesis and release of anterior pituitary 
luteinizing hormone (LH) occurs, followed by cessation of ovulatory cycles in most 
mares [36]. 
Continuous infusions of GnRH into mares from mid-January or later can 
effectively induce secretion of LH and follicle development in winter anovulatory mares 
[11, 37]. These results imply that a reduction in secretion of GnRH is the likely limiting 
factor during seasonal anovulation. In addition, the ability of pituitary gonadotropes to 
respond to GnRH changes as the winter anovulatory period progresses, with a lesser 
response in late February compared to late December [11, 38]. However, it is not known 
whether this occurs as a result of innate changes in gonadotrope responsiveness to GnRH 
or due to chronic inactivity of cellular machinery following an extended period of 
limited exposure to GnRH.  
The measurement of pulsatile release of both GnRH and LH in the mare can be 
made using the technique of ICS cannulation developed by Irvine [39], which allows 
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sampling from the anterior pituitary draining vein effluent. More recently, the technique 
has been used by Cooper et al. [13] and Velez et al. [11] in our laboratory. In the former 
case, it was observed that the marked decline in secretion of LH in winter was not 
accompanied by similar declines in ICS concentrations or pulsatile release of GnRH 
[13]. However, these data remain controversial and additional critical research steps are 
necessary in order to confirm their accuracy. 
2.2 Potential roles for seasonality in reproduction of the mare  
2.2.1 Natural and artificial photoperiods 
It is well accepted that photoperiod is a major regulator of seasonality in horses 
and, over the years, investigations have focused on its different physiological effects. 
Regardless of whether lighting conditions are considered inhibitory or stimulatory, 
mares exposed to constant lighting conditions become refractory to that signal and their 
circannual reproductive rhythms resume [40, 41, 42]. This can be overcome by exposing 
the animal to periods of light and dark at regular intervals. Mares exposed to artificial 
lighting that extends day-length to 15-16 h during the winter and early spring exhibit an 
accelerated onset of the breeding season, which reinforces the influence and advantage 
of artificial lighting [43]. However, mares exposed continuously to 16 h of light and 8 h 
of darkness eventually return to anestrus [40, 41, 42].  
Several early studies utilized different combinations of light and dark periods 
with the objective of determining which would induce ovulation in anovulatory mares 
[41, 44, 45, 46, 47]. When intact anovulatory mares were exposed to increasing 
photoperiod using artificial lighting, the first ovulation occurred earlier [48]. The 
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approaches used different combinations of light and dark periods in an effort to optimize 
the hastening of ovulation [40, 41, 42, 43, 44, 45, 46, 47]. However, variations in the 
circadian rhythms of animals in experimental conditions mimicking the perception of 
sunrise and sunset, which is important for the placement of the photosensitive phase, are 
different to those compared to natural conditions. Thus, it can be concluded that it is not 
possible to completely duplicate this situation under experimental conditions [49].  
2.2.2 Importance of nutrition  
The influence of body condition score on the average interval to first ovulation of 
the breeding season [50] becomes apparent when mares are supplemented with high 
concentrate diets. Mares ovulated earlier in the spring transition under this regimen and 
when BW gain was promoted during the early spring [51, 52]. The combination of diet 
supplementation and artificially extended photoperiod also positively influence the onset 
of reproductive activity in the spring [53]. Moreover, mares in low body condition 
exposed to a high-dietary energy intake and improving body condition during spring 
transition had a shortened interval to first ovulation [54]. Mares grazing on pasture with 
grass of high quality exhibit a similar phenomenon [55]. 
2.2.3 Role of melatonin 
Melatonin is a key hormone controlling seasonal reproduction in mammals. 
Studies demonstrating that the pineal gland translates photoperiodic signals received by 
the eyes to other endocrine effects through changes in melatonin secretion were 
important for our current understanding of mechanisms regulating seasonal reproduction 
in horses and other mammals [56, 57, 58]. Production of melatonin from pineal explants 
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collected throughout the year is greater in December and January and returns to lower, 
breeding season values by February [43, 57, 59]. This observation corresponds to similar 
changes in concentrations of hydroxyl-indole-o methyl transferase (HIOMT), the 
enzyme involved in the synthesis of melatonin in the pineal [59]. The pattern and 
duration of melatonin secretion can be changed when mares are exposed to artificial 
light during the natural dark phase [44, 57]. 
Mares which were pinealectomized and exposed to an extended photoperiod did 
not exhibit hastening of reproduction transition [60], and treatment with melatonin 
results in a similar effect [44, 57]. In addition, mares treated with melatonin implants did 
not exhibit any ovarian effects when implanted on the shortest day of the year, but onset 
of the breeding season was advanced when treatments were applied close to the summer 
solstice [58]. Exogenous melatonin has been shown to affect hypothalamic 
concentrations of GnRH when injected in ovariectomized mares during breeding season 
and in sheep [61, 62]. However, conclusions drawn from such studies appear to be in 
conflict with others in which melatonin seemed to affect circannual rhythms rather than 
reproductive activity directly [49]. 
2.2.4 Patterns of LH and GnRH secretion 
Several studies have provided evidence that the photoperiodic regulation of 
equine seasonal reproduction is steroid-independent [63, 64]. The secretion of LH in 
intact and ovariectomized mares has been shown to follow a seasonal pattern, with 
increased secretion during the breeding season and decreased secretion during the 
anovulatory period [65, 66, 67, 68]. However, there does not appear to be a similar 
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pattern of change for follicle stimulating hormone (FSH) [67]; although, minor changes 
have been observed [38]. Mares injected with GnRH during the transition period from 
the anovulatory phase into the breeding season had release of LH and FSH stimulated 
[69].  
 During the spring transition period, before first ovulation of the breeding season, 
mares often exhibit prolonged periods of estrous behavior in the absence of significant 
ovarian activity. However, mean circulating concentrations of LH remain relatively low 
until 6-7 days before the first ovulation [66, 67]. 
A reduction in hypothalamic content of GnRH in anovulatory mares is correlated 
with low stores of LH in the anterior pituitary during late winter [70]. However, the 
restoration in GnRH concentrations has been shown to occur earlier in the spring than 
restoration of pituitary LH. Maximal adenohypophyseal concentrations of LH are not 
observed, until mid-breeding season [70, 71]. Additionally, there appear to be 
differences in hypothalamic distribution of GnRH immunoreactivity during the breeding 
and non-breeding seasons and, in spite of findings in our own laboratory, there is 
evidence that the release of GnRH during the anovulatory season is reduced [71]. In the 
horse and some other species, LH response to exogenous GnRH is used to estimate 
pituitary responsiveness to endogenous GnRH. Mares in different reproductive states 
received different doses of GnRH which induced pulsatile LH secretion comparable to 
what is observed endogenously, implying that the differences observed in concentration 
of LH between seasons is due to a difference in endogenous GnRH secretion [72]. 
Moreover, a difference in overall mean secretory rate of GnRH among groups in their 
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breeding and non-breeding seasons was observed using the push-pull perfusion technic 
[73]. 
In sheep, estradiol plays a definitive role in reproductive seasonality. During the 
non-breeding season, there is an increase in the negative feedback sensitivity to estradiol 
through activation of the dopaminergic system and consequent suppression of the 
pulsatile release of GnRH and LH [74]. To the contrary, when mares were treated 
chronically with estradiol during nonbreeding season, mean concentrations of LH 
increased [64]. This indicates that winter anestrous is independent of estradiol negative 
feedback in the mare.  
2.2.5 Thyroid hormone 
Thyroid hormones have been demonstrated to contribute to the regulation of 
seasonal breeding in some species, such as sheep [75]. Thyroidectomy abolishes the 
reduction in episodic release of LH that occurs in intact ewes at the end of the breeding 
season. However, secretion of LH was similar in intact and thyroidectomized ewes 
during the breeding season [75]. The requirement for thyroid hormones occurs only 
during a small window of time at the end of the breeding season in ewes [76]. The 
secretion of LH can be inhibited in ewes thyroidectomized late in the breeding season 
and then treated centrally with thyroxine (T4) [77]. The role of thyroid hormones in the 
mare has not been extensively studied. Circulating concentrations of thyroid hormones 
in horses are greatest during the winter compared to other seasons [78]. Unlike sheep 
[77], thyroidectomy does not alter timing of the onset of the anovulatory season in 
mares.  
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2.3 Circannual clock mechanisms  
The study of circannual clock mechanisms is an recognized concept based on a 
working hypothesis involving the existence of adult stem cells in the brain, pituitary 
gland, and some peripheral tissues that appear to undergo synchronized division [79]. 
These cells proliferate, migrate and differentiate, providing the necessary substrate for 
specific physiological changes over time, and have cell death as a trigger for the 
beginning of the following cycle. This model has been characterized in species such as 
primates including human [80, 81], and in several hibernating [82, 83, 84, 85, 86, 87], 
seasonal breeding [88, 89] and seasonal migratory [90, 91, 92] species.  
No changes in the circannual rhythm have been observed when seasonal animals 
(birds, mammals, and insects) were maintained in a constant light and dark cycle that are 
different from the natural exposure to a 24 h day (e.g. 23 or 25 h d) [90, 93, 94, 95]. The 
ability of the nervous system to monitor photoperiodic time enables the system to detect 
the annual cycle of day-length and synchronizes physiological changes throughout 
seasons which are dependent on the endogenous circadian system. When photoperiod 
changes it is possible to observe activation or inhibition of seasonal responses, or 
alteration of endogenous circannual rhythm generators that synchronize with the 
environment in a long term fashion [96, 97, 98].  
The suprachiasmatic nucleus (SCN) serves as a pacemaker timing the circannual 
rhythm including activity and sleep, body temperature, pituitary activity, among other 
diurnal and nocturnal rhythmicity involving melatonin activity. This occurs by 
influencing the timing of duration of the melatonin rhythm. This also influences the 
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reading of melatonin signals by the pars tuberalis (PT), one of the more well-studied 
targets in which circadian clock genes have been characterized [99]. The location of the 
PT, and the fact that it is a melatonin target tissue with a high density of melatonin 
receptors, makes it a specialized site for regulating the circannual clock [100, 101]. It 
appears to function as a regulator of long-term cycles in several physiological systems. 
For example, some specialized PT cells (PT thyrotropes) [102] are responsible for TSH 
secretion, which acts locally in the pituitary gland and regulates thyroid hormone 
dependent mechanisms [97, 103]. In mammals, information sent from the retina to the 
SCN coordinating the production of melatonin by the pineal gland in a 24 h period, is the 
mechanism coding photoperiod [90, 104]. 
The endogenous circannual rhythm, driven by specific genes, drives seasonal 
reproductive cycles in sheep, and these cycles are maintained even under constant 
photoperiod [105]. This phenomenon is termed the photorefractory response. Procedures 
such as pinealectomy or denervation of the pineal through superior cervical 
ganglionectomy can be utilized to dissociate the circannual and circadian timing 
systems. The operations remove the melatonin signal and thus block physiological 
responses to photoperiod [98, 106]. Specific clock genes controlling secretion of GnRH 
in the hypothalamus, unlike those in the PT, have not been characterized. 
One of the limiting factors for the study of the circannual clock is length of time 
required to observe changes within or between fractions of a circannual cycle compared 
to those needed for typical neuroendocrine feedback loops [107]. The minimal time for 
observing these changes is dependent on cyclical tissue regeneration. The theory 
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underlying this process has been termed the “histogenesis hypothesis” [79]. Photoperiod 
and other environmental cues are responsible for modulating these regenerative cycles, 
and may do so by suppressing or prolonging the proliferative phase of new cells. These 
processes are analogous to observed changes in response to daily light signals that affect 
the rhythmic expression of clock genes [108].  
The histogenesis hypothesis considers regenerative mechanisms in the brain, 
pituitary, and in peripheral body organs that are involved in the control of circannual 
rhythms. The model shows that all tissues have certain autonomy in regenerating their 
own cells and contributing to long-term timing of some physiological cycles [79]. In 
sheep, this system is synchronized by the PT and mediobasal hypothalamus, and 
coordinated by the SCN which controls the functional state of the whole body through 
circannual pacemakers [79]. 
2.4 The role of endogenous opioid peptides 
Endogenous opioid peptides (EOP) were the first to be classified and identified 
as hypothalamic inhibitory peptidergic signals regulating pituitary secretion of LH [109, 
110, 111]. They have been divided into three classes of biological activity according to 
the hypothalamic regions in which they were found [112, 113,114, 115, 116]. However, 
all of these classes overlap in regions that are innervated by GnRH neurons and have 
shown the ability to inhibit secretion of LH when studied in ovariectomized rats [110, 
111,117]. It has also been proposed that the EOP system may influence the neural clock 
and its ability to govern GnRH surges in rats [118]. Numerous studies have examined 
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the influence of EOP on the hypothalamic secretion of GnRH and its subsequent effects 
on gonadotropin release [119, 120, 121].  
The EOP antagonist naloxone has positive effects on secretion of LH in several 
species, including in mares during the luteal phase [122] and anovulatory season [121], 
and in the human [123], sheep [124, 125, 126], and pig [127]. A relationship between 
opioid inhibition and progesterone has been observed in cyclic mares [122, 128] as well 
as other species [123, 127, 125, 126]. Other investigators have shown that the release of 
opioids is independent of ovarian steroids [121], and in some animal models (e.g., 
anovulatory mature sheep) naloxone failed to have any effect on release of LH [124, 
129]. 
2.5 Potential role for GnIH/RFRP3 in reproductive seasonality 
2.5.1 Localization and peptide sequence 
One of the more recent developments in reproductive endocrinology has been the 
discovery of new family of hypothalamic signaling peptides, the RF-amide related 
peptide (RFRP). RF-related peptide 3(RFRP3), a peptide capable of suppressing the 
secretion of LH in birds and subsequently named gonadotropin-inhibiting hormone 
(GnIH), was the first RFRP identified and described by Tsutsui et al. in 2000 [14]. A 
number of studies have indicated that GnIH may play an important role in the seasonal 
regulation of reproduction of avian species [14, 17, 24, 29, 30, 130, 131] through its 
ability to control secretion of LH.  
Immunohistochemical evidence of this peptide has been demonstrated in the 
hypothalamus [23]. Investigations in the brains of mammals, amphibians, and fish 
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followed these initial reports [17, 18, 19, 20, 21, 22]. As a result, 3 RF-amide related 
peptides (RFRP1, 2 and 3), with RFRP3 being the homolog of GnIH, and GnIH/RFRP3 
receptors (GPR147, OT7T022, and GPR74) [19] have been observed and characterized 
in numerous species [17, 18, 19, 20, 21, 22, 24, 25, 26, 130, 132, 133, 134].  
In our laboratory, we have demonstrated that RFRP3-immunoreactive neurons 
(Fig. 1A) are located in the dorsomedial hypothalamus, similar to that reported 
previously in other mammalian species [17, 18, 19, 20, 135]. It was also observed that 
RFRP3-immunoreactive neuronal fibers are in close proximity to GnRH neuronal cell 
bodies and dendrites (Fig. 1B), supporting a potential role for synaptic regulation of 
GnRH neurons by RFRP3. The presence of RFRP3-immunoreactivity was also observed 
in the infundibulum, a classical site for the release of neurohormones (releasing and 
inhibiting hormones) into the hypothalamic-hypophyseal portal vasculature for 
regulating adenohypophyseal function. Using the equine genomic sequence homologous 
to avian GnIH, an equine-specific primer was designed for the equine RFRP and a 
partial cDNA sequence of approximately 420 bp was amplified by PCR as shown in Fig. 
2 [Amstalden et al unpublished data].  
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Fig. 1.(A) GnIH-immunoreactive neurons in the dorsomedial nucleus of the equine 
hypothalamus (arrows). (B) Double-label immunocytochemistry for GnRH (brown) and 
GnIH (purple) in equine hypothalamic sections. The close proximity of GnIH containing 
fibers to GnRH dendrites (arrow) and the cell body (arrow head) can be observed in the 
photomicrograph [Amstalden, Bentley and Williams unpublished observations]. 
 
 
 
 
Fig. 2. Amplification of RFRP3 and RFRP3 receptor from equine hypothalamic cDNA. 
PRC products of approximately 420 BP were generated using primers specific for equine 
sequences [Amstalden, Bentley, and Williams unpublished observations]. 
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 When GnIH was first characterized in quail, most of the GnIH immunoreactive 
fibers were observed in the median eminence (ME) of the hypothalamus, and in the 
dorsal motor nucleus of the vagus in the medulla oblongata [136]. Moreover, when 
investigated in sheep, RFRP3-containing hypothalamic neuronal fibers were shown to 
project extensively into the neurosecretory zone of the ME [18]. Additionally, in 
hamsters it could be observed that these fibers were scattered in the inner layer of the 
same area [20]. 
The structure of RFRP peptides always possesses a LPXRF-amide sequence, 
where X represents L or Q with a C-terminal in common. The horse sequences are 
similar to the ones observed in humans, and sheep, containing the predicted pre-protein 
with RF-amide related peptides, and one RFRP-like sequence [17, 18, 20]. However, the 
mammalian homologue differs in amino acid sequence from that of avian [19, 23, 24, 
25, 26, 27]. Therefore, the GnIH-related peptide discussed herein will be referred to as 
RFRP3 until full characterization of their physiological function is determined in 
mammalian species.  
2.5.2 GnIH/RFRP3 effects on GnRH and LH release 
Having confirmed the presence of GnIH and its homologs in several species [14, 
18, 20, 30, 137], additional research was undertaken to understand their roles in 
reproduction and other physiological processes. Peptides related to the GnIH/RFRP 
family originate in the paraventricular nucleus (PVN), which appears to be the only 
source of GnIH production. In several bird species, some fiber terminals extend to the 
external layer of the ME where they play a role in controlling pituitary gonadotropin 
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secretion [17, 29, 30, 31, 131, 138]. However, in Syrian hamsters GnIH fibers have been 
observed primarily in the internal rather than external layer of the ME [20]. This 
observation indicates that GnIH might not be able to reach the necessary vessels to 
regulate pituitary secretion [17, 20]. GnIH immunoreactivity exhibits marked changes 
across seasons in seasonal breeding birds and rodents [17, 139]. 
The role of GnIH/RFRP3 in regulating GnRH release has been demonstrated by 
GnIH neurons making axosomatic contact with GnRH neurons, putatively decreasing the 
release of GnRH release in avian and mammalian species [31, 134, 139]. When tissue 
from the preoptic area of male rats was double-labeled and stained for GnRH and 
RFRP3, a mean of 75% of GnRH cell bodies were shown to be in contact with RFRP3 
fibers [24]. Moreover, in mice RFRP3 appears to directly inhibit the firing rate of a 
proportion of GnRH cells [140]. 
Despite evidence that GnIH/RFRP3 may directly affect function of GnRH 
neurons, additional observations have indicated expression of the peptide’s receptor on 
gonadotropes and direct effects on secretion of LH at the adenohypophyseal level [31, 
33, 138]. In order to explain how RFRP3 may affect pituitary gonadotropes, it is 
instructive to understand the mechanism of GnRH-induced release of LH. Following 
GnRH receptor binding there is an increase in intracellular inositol triphosphate [141, 
142], which promotes Ca2+ discharge from intracellular Ca2+ through opening of calcium 
channels [143]. With the increase in cytoplasmic calcium influx, LH release is 
stimulated [141, 142]. Clarke et al [18] has shown that when sheep pituitary gland cell 
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cultures are treated with RFRP3, the generation of the intracellular free calcium required 
for LH release is blocked.  
Additional studies have demonstrated that GnIH/RFRP3 reduces LH release even 
when its release is stimulated by exogenous GnRH [35, 144]. After continuous infusion 
of different doses of GnIH via osmotic pumps for 2 wk in mature male quail, a decrease 
in LH concentration in the plasma from peripheral blood was observed [145]. 
Furthermore, inhibition of LH secretion has been shown in pituitary cell cultures of male 
quail [29], rat [35], chicken [146], and sheep [18], when treated with RFRP3. After 
infusing RFRP3/GnIH in hamsters [17, 20], and in rats [34, 35, 147], centrally or 
peripherally, serum concentrations of LH also decrease. In addition, castrated and 
photostimulated, white-crowned sparrows treated with quail GnIH showed a rapid 
decrease of LH concentration in plasma [131]. Because the quail sequence was effective 
in song sparrows and white-crowned sparrows [131], it seems that GnIH is 
heterospecific. When injected intravenously (i.v.) in ovariectomized [35, 144], and intact 
rats [137], in ewes [14], and in castrated male calves [33], RFRP3 suppresses the 
pulsatile release of LH and mean concentration of LH. All these results reinforced the 
suggestion that the RFRP3 may have its main action at the pituitary level. 
2.5.3 Dose response relationship for GnIH/RFRP3 
Among experiments indicating the presence, localization, and effects of 
GnIH/RFRP3, several have focused on dose relationships in vivo and in vitro in different 
species. In sheep pituitary cell cultures, RFRP3 appears to have effects at picomolar 
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concentrations [18]. This is somewhat anomalous to most other physiologically-active 
peptides which generally act in the nanomolar range [e.g., kisspeptin; 148]. 
When given as i.v. injections, RFRP3/GnIH has been shown to be effective in 
suppressing either circulating concentrations of LH or its pulsatile release at a dose of 1 
µg in rats [35]. In sheep, a loading dose of 50 μg followed by a continuous infusion of 
200 μg for over 1 h was effective in suppressing LH release [18]. Effective doses of 600 
ng in Syrian hamsters [20], 1,000 ng in male song sparrows [131], and 90 μg injected 
every 10 min for 1 h in male calves has been observed [33]. Furthermore, 
intracerebroventricular (i.c.v.) injections of 0, 100, 300, or 500 ng were tested in 
ovariectomized Syrian hamsters [20]. However, only the concentration of 500ng was 
observed to be effective in this species.  
2.5.4 Potential role of RFRP3 in feeding behavior 
The RF-amide family of peptides may also play roles in the control of feeding 
behavior. Whether such effects will prove to be as important as those involving 
reproduction [137, 145, 147, 149, 150], prolactin release [32, 151, 152], or blood 
pressure [153] (effects that have been related to the entire RF-amide family) remains to 
be determined. However, studies in a wide range of species, including mammals, have 
shown that at least 3 of 5 known mammalian genes encoding for peptides of the RF-
amide family have cognate receptors that are compatible with a physiological role in 
feeding behavior [154]. In rats and chicks treated with RFRP3, food intake was 
significantly increased [137, 155]. 
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2.5.5 Melatonin effects on GnIH/RFRP3 
Melatonin plays an important role in reproduction of seasonal-breeding animals 
through annual changes in pineal physiology [2, 156, 157, 158, 159, 160]. However, a 
functional link between melatonin secretion and GnIH [56, 161, 162, 163] has not been 
fully described. When melatonin concentrations were experimentally decreased in quail 
a concomitant decrease in the expression of GnIH precursor mRNA in the diencephalon 
was observed [130]. Therefore, it seems that GnIH expression is induced by a direct 
action of melatonin on GnIH neurons via its receptor. Moreover, the role of melatonin in 
the regulation of GnIH release and its correlation with LH release in quail has also been 
investigated. Administration of melatonin in varying doses to hypothalamic explants 
resulted in an increase in GnIH release, particularly in explants collected from animals 
exposed to long day photoperiods and incubated in dark conditions [130]. In addition, 
experiments in hamsters indicate that the expression of RFRP3 genes may be controlled 
by melatonin [164]. 
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CHAPTER III 
EFFECTS OF MAMMALIAN HOMOLOGUES OF GONADOTROPIN-
INHIBITING HORMONE ON SECRETION OF LH IN THE MARE 
 
 
 
3.1 Introduction 
Reproductive seasonality in the equine species has been studied for several 
decades. However, the changes that occur in the hypothalamic-hypophyseal axis to 
regulate the different secretion patterns of gonadotropic hormones, particularly LH, 
observed during the breeding season and the anovulatory period have not been 
completely elucidated [11].  
Methods to achieve an earlier spring transition by manipulating photoperiod with 
artificial lighting have been successful and adopted by the equine breeding industry [1]. 
The basis of this effect is through neural impulses traveling from photoreceptors in the 
eye through the suprachiasmatic nucleus (SCN) and superior cervical ganglion (SCG) to 
the pineal gland [104,165]. The latter process regulates pineal synthesis and secretion of 
melatonin which influences hypothalamic secretion of GnRH through currently 
undefined mechanisms. 
A direct effect of melatonin on secretion of GnRH, which drives synthesis and 
secretion of both LH and FSH has not been demonstrated [2, 5]. Nonetheless, studies 
reported by Irvine and Alexander [72], utilizing the intercavernous sinus cannulation 
(ICS) technique, as well as others using push-pull perfusion [73], have concluded that 
the secretion of GnRH is decreased during the winter anovulatory period. Work in our 
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laboratory using the ICS technique, which sampled mares throughout the four seasons, 
has failed to confirm those findings [13]. Nonetheless, when seasonal anovulatory mares 
are infused hourly [9, 166] or continuously [37, 38] with native GnRH, anterior pituitary 
secretion of LH is dramatically increased, follicular development follows, and 
spontaneous ovulation occurs at a high frequency [11, 37, 38]. Therefore, speculations as 
to whether GnRH is limiting in winter or whether the gonadotrope becomes more 
resistant to an uninterrupted, endogenous secretion of GnRH in the horse have persisted. 
The RF-amide family of peptides (RF-related peptides 1, 2, and 3) has been 
shown to regulate various physiological functions, including food intake and 
reproduction [34, 137, 145, 147, 149, 150, 154, 155]. The functionality and regulation of 
reproduction by one of these peptides, RFRP3, was first characterized and investigated 
in the quail. In avian species RFRP3 has been named gonadotropin-inhibiting hormone 
(GnIH) due to its suppressive effects on the release of LH [14]. Moreover, GnIH has 
been proposed to function as a major regulator of reproductive seasonality in seasonally-
breeding birds [14, 131], and could play a similar role in seasonally-breeding mammals 
[18, 20]. In some mammalian species, GnIH and its mammalian homologue (RFRP3) 
have been shown to suppress the secretion of LH and adenohypophyseal responsiveness 
to GnRH [18, 19, 20] in a dose-dependent manner. Thus, if RFRP3 regulates seasonality 
in mammals, it may do so by direct effects at the anterior pituitary. As a first step in 
testing this hypothesis in mares, studies presented herein determined whether the 
predicted sequence for equine RFRP3 (eRFRP3), or the sheep homologue of GnIH 
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(oRFRP3), could disrupt the endogenous secretion and GnRH-induced release of LH in 
mares during different physiological conditions. 
3.2 Materials and methods  
All experiments had animal-related procedures approved by the Institutional 
Agricultural Animal Care and Use Committee (IAACUC) of the Texas A&M University 
System.   
3.2.1 Experiment 1 
Preliminary Study: Equine RFRP3 (eRFP3) effects on peripheral plasma LH in 
GnRH-treated mares during the luteal phase.  
3.2.1.1 Hypothesis 
Administration of eRFRP3 suppresses mean concentrations of LH during 
continuous infusion of GnRH.  
3.2.1.2 Specific objectives 
Determine whether eRFRP3 effectively suppresses mean peripheral 
concentrations of LH of mares in the luteal phase while treated continuously with native 
GnRH (20µg/h) to create an LH secretion pattern similar to that observed during the 
follicular phase [11]. 
3.2.1.3 Animals and study location 
Six Quarter Horse mares ranging from 350-590 kg body weight and 2-19 years of 
age provided by local breeders were maintained on pasture (Coastal Bermuda grass) at 
Texas AgriLife Research-Beeville and supplemented with a mixed grain concentrate 
(12% crude protein; Falls City Milling, Falls City, TX) to maintain body condition score 
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between 5 and 6 on a 1 to 9 scale. Mares were teased daily with a stallion, and the day of 
ovulation was determined by transrectal ultrasonography. Three days after ovulation, 
mares received a subcutaneous osmotic pump (Alzet 2ML1; Durect Corp., Cupertino, 
CA) delivering native GnRH (20 µg/h) diluted in saline continuously for 7 d (Fig. 3). A 
jugular catheter was also inserted at this time and sutured to the neck using aseptic 
technique. Mares were assigned in a replicated Latin square design to receive saline, 500 
or 1000µg of eRFRP3 (Table 1). 
 
 
 
 
Fig. 3. Time line for experiment relative to ovulation day. 
 
 
 
Table 1: Schedule relative to RFRP3 treatment and sampling. 
Mares Day of Luteal Phase 
 4 6 8 
1 and 6 A1 A6 B1 B6 C1 C6 
5 and 4 B5 B4 C5 C4 A5 A4 
3 and 2 C3 C2 A3 A2 B3 B2 
                                      Treatments : A= saline; B=500µg of RFRP3; C= 1000µg of RFRP3. 
 
 
 
 On the day of sampling, mares were tied loosely and provided water and hay 
during the sampling procedure. Jugular blood (12 mL) samples were collected every 15 
 
// 
Pump Removed Ovulation Catheterization/ 
Pump Insertion 
Blood Sampling 
d0 d3 d4, 6, and 8 d9 
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min for 4 h for determination of mean concentrations of LH by radioimmunoassay 
(RIA). Mares were heparinized (40,000 IU sodium heparin, i.v.) daily to prevent clot 
formation in the jugular catheter. The catheter was also flushed with 2.0 mL (void 
volume of cannula and extension) of a heparinized solution containing 300 IU/mL 
following each collected sample. Samples were placed into tubes containing 50µL of a 
5% EDTA-heparin solution (10,000 IU/mL) to prevent coagulation and were kept on ice 
until centrifugation for plasma collection after harvesting. Plasma was stored at -20º C 
until hormone analysis. Jugular cannulation and pump insertion were performed as 
described in 3.2.1.4.  
3.2.1.4 Alzet osmotic pump insertion and jugular catheterization 
 Two days after ovulation was observed (day 3 of the luteal phase), the mare was 
placed in a stock and an area above to the point of the shoulder measuring approximately 
5 x 5 cm was clipped, scrubbed with an iodophore, and disinfected with tame iodine 
solution. Hands were scrubbed and sterile surgeon’s gloves were worn. Anesthesia was 
performed with a solution of Lidocaine HCl (2%; 3-5 mL), Vedco, Inc, St Joseph, MO, 
injected subcutaneously). A 1.5-cm incision was made through the skin with a sterile 
scalpel. A pocket was created under the skin with a sterile blunt instrument to 
accommodate the Alzet osmotic pump. On the jugular groove an area measuring 
approximately 2 x 4 cm was clipped and disinfected as described above. A 12-gauge 
needle was inserted in the jugular vein and a polyethylene catheter (Becton Dickinson 
and Company, Sparks, MD) was inserted through the needle and sutured to the skin after 
the needle was removed. To close both incisions a non-absorbable (encased nylon 
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polyamide (RXVeterinary, Grapevine, TX)) suture (No. 2) was used. The areas were 
dressed with an approved wound dressing for horses. After the completion of the 
sampling schedule described in 3.2.1.3 the i.v. catheter and the pump were removed 
through the re-opening of the same incision, which were closed again with the non-
absorbable suture. Suture was removed after 7 d.  
3.2.1.5 eRFRP3 sequence synthesis and doses 
  Using primers for the eRFRP gene, a partial cDNA sequence of approximately 
420 bp was amplified by PCR and cloned into a vector. The predicted sequence of the 
eRFRP3 has been determined to be Ile-Pro-Asn-Leu-Pro-Gln-Arg-Phe-NH2. The 
peptide was synthesized by AUSPEP Clinical Peptides (Tullamarine Victoria, Australia) 
and used for this and the subsequent studies. Peptide validation was performed by high-
performance liquid chromatography and mass spectral analysis (98% of purity and 983 
of molecular weight). Doses used in this experiment were determined by extrapolating, 
based on BW, from doses used previously in other species such as sheep [18] and cattle 
[33]. The peptide was delivered in a bolus i.v. injection at the onset of sample period.  
3.2.1.6 Hormone analysis 
  Concentrations of LH in plasma of all samples were determined by double 
antibody RIA validated previously in this laboratory [37]. For preparation of iodinated 
(I125) tracer and standard (0.1, 0.2, 0.4, 0.8, 1.0, 2.5, 5.0, 10.0, and 20.0 ng/mL), a highly 
purified equine LH (eLH AFP-5130A) was used. A specific equine LH antiserum (AFP-
240580Rb) at a dilution of 1:125,000 yielding an average binding (B/B0) of ~ 32.5% 
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was employed. Minimum detectable concentration was 0.1 ng/mL with mean intra- and 
inter-assay CV of 6.4 % (± 0.8) and 6.4%, respectively. 
3.2.1.7 Statistical analysis 
The effect of treatments on concentrations of LH was analyzed utilizing the 
GLM procedure of the Statistical Analysis System (SAS Inst., Inc., Cary, NC). The 
statistical model tested the effect of RFRP3 dose on mean concentrations of LH, using 
mare as the subject and time as the repeated variable.  
3.2.2 Experiment 2 
Pattern of LH secretion in pituitary venous effluent of the intercavernous sinus 
(ICS) of follicular phase mares treated chronically with eRFRP3 followed by a GnRH 
challenge. 
3.2.2.1 Hypothesis 
Chronic administration of eRFRP3 disrupts the episodic release pattern of LH 
release in the ICS and suppresses GnRH-induced release of LH.  
3.2.2.2 Specific objectives 
Determine the effect of chronic administration of 250µg of eRFRP3, injected i.v. 
every 10 min for 6 h, on 1) the episodic pattern of LH release in mares during the 
follicular phase of the estrous cycle, and 2) GnRH-mediated release of LH. The dose of 
eRFRP3 was determined on the basis of BW by extrapolation from previous studies in 
smaller species as indicated in 3.2.1.5.  
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3.2.2.3 Animals and study location 
Thirteen Quarter Horse mares, ranging from 350-590 kg and 2-17 yr of age, were 
maintained on pasture (Coastal Bermuda grass) at Texas AgriLife Research-Beeville and 
supplemented with a mixed grain concentrate (12% crude protein; Falls City Milling, 
Falls City, TX) to maintain body condition score between 5 and 6 in a scale from 1 to 9. 
The day of ovulation was determined as described in 3.2.1.3. On day 7 after ovulation, 
mares were treated intramuscularly (i.m.) with 2 mL prostaglandin F2α (PGF; 10 mg 
Lutalyse, Pfizer, New York, NY) to regress the corpus luteum (CL). The following day, 
the intercavernous sinus (ICS) of each mare was catheterized via the superficial facial 
vein using aseptic technique (Fig. 4). Mares were assigned randomly to one of two 
groups: 1) Control: 3 mL saline i.v. every 10 min for 8 h (n=6); or 2) eRFRP3 (n=7); 
saline every 10 min for 2 h (Period I), followed by 250 µg eRFRP3 in 3 mL saline every 
10 min for 6 h (Period II).  Six milliliter blood samples were collected at 5-min intervals 
for 6 h. At min 365 all mares were then administered a single i.v. injection of 1 mg 
GnRH and ICS blood samples were collected at 15 min intervals for an additional 2 h 
(Period III; Fig. 4).   
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Fig. 4. Time line for experiment relative to day of ovulation and for experiment relative 
to sampling period. 
 
 
 
 On the day of sampling, mares were tied loosely, and provided water and hay 
during the sampling period. A volume of 6 mL of ICS blood was collected every 5 min. 
Mares were heparinized (40,000 IU sodium heparin, i.v.) at the beginning of the 
sampling period and also had the cannula flushed with 1.5 mL of heparinized saline (300 
IU/mL) after each sample was collected. Samples were placed into tubes containing 
50µL of a 5% EDTA-heparin solution (10,000 IU/mL) to prevent coagulation, placed 
immediately on ice and centrifuged for plasma collection every hour after harvesting. 
Plasma was stored at -20º C until analysis of LH. ICS cannulation was performed as 
described in 3.2.2.4. 
3.2.2.4 Intercavernous sinus (ICS) catheterization procedure 
 On the day following regression of the CL, the ICS was catheterized as describe 
previously by Irvine et al., Cooper et al. and Velez et al. [11, 13, 39] for assessing the 
pulsatile pattern of LH release in anterior pituitary venous effluent. The mare was placed 
Sampling every 5 
min 
RFRP3 or 
Saline every 10 
min/ sampling 
every 5 min 
GnRH at min 360/ 
RFRP3 or Saline 
every 10 min/ 
sampling every 15 
min 
0 – 120 min 
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125 – 360 min 
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365 – 480 min 
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d0 d7 d8 d9 
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// 
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in a stock and sedated with detomidine HCl (0.5 to 1 mL of 10 mg/mL of solution (20-
40 µg/kg BW)). The area that lies parallel and along the anterior border of the mandible, 
over the facial vein and extending in all directions (approximately 2 to 2.5 cm), was 
clipped, scrubbed, and disinfected for aseptic surgery.  The facial vein was palpated 
through the skin and an area below the facial crest, which overlies and surrounds the 
vein (approximately 1.5 cm x 1.5 cm), was infiltrated subcutaneously with Lidocaine 
HCl (2%, Vedco, Inc, St Joseph, MO). A skin incision measuring approximately 1 cm 
was made over the vein, and the vein was exteriorized with a blunt dissection and held in 
this position by placing a sterile rod between the vein and the underlying tissue. A small 
incision was made in the vein using the point of the scalpel blade (number 10) and 
Tygon tubing measuring 38 cm (Norton Performance Plastics CO, Akron, OH; 0.1 cm 
ID x 0.2 cm OD), with a flexible J-straight guide wire inserted into, were inserted into 
the vein up to the point where resistance was felt. The resistance point usually occurs 
after 18 and 20 cm of tubing has been inserted. Once in place, a lateral radiograph was 
taken to visualize the position of the catheter and verify its location just behind and 
below the eye. Adjustments in catheter position were made as required. The guide wire 
was removed and a heparin (10,000 IU/mL) lock was placed in the tubing. The tubing 
was sutured to the edge of the incision with synthetic, non-absorbable suture above and 
below its exit. The skin incision was sutured partially closed and the wound is treated 
with an antiseptic skin dressing. The catheter was removed immediately after completion 
of intensive sampling. The skin area in front of the mandible where the tubing was 
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located was then treated daily with a topical antiseptic. Sutures were removed after 7 to 
10 d. 
3.2.2.5 Hormone analysis 
 Radioimmunoassay for LH was the same as for experiment 1. Mean intra- and 
inter-assay CV averaged 6.8% (±1.3) and 5.8%, respectively. 
3.2.2.6 Statistical analysis 
Because available pulse detection algorithms have not proven reliable in our 
hands for accurately detecting pulsatile release patterns of LH in horses, a different 
approach for detecting significant secretory episodes was employed. Luteinizing 
hormone data were transformed to a 3-point rolling average which reduced background 
noise. To be considered an episode, the coefficient of variation (CV) of the ascending 
and the descending sides of pultative episodes were required to be greater than the intra-
assay CV.  Once the episodes were identified, amplitude, frequency, and duration of 
each episode were determined. An expression for area under the curve for concentrations 
of LH after GnRH injection was delivered was as follows: 
 
 The area under the curve created between y=f(x) axis and x-axis was given by 
the definite integral above. Values for a and b were determined by where the curve was 
located in the x-axis. 
Data were analyzed using the GLM procedure of SAS (SAS Inst., Inc., Cary, 
NC) to determine the effects of RFRP3 treatments on frequency, duration, and amplitude 
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of the episodes and the effect of GnRH challenge on the area under the LH curve. The 
statistical model for the repeated measures analyses included treatment as the main 
effect, period or time by treatment, and mare within treatment as the subject. 
3.2.3 Experiment 3 
Ability of a suprapharmacological dose of eRFRP3 to suppress secretion of LH 
in anovulatory mares treated continuously with GnRH. 
3.2.3.1 Hypothesis 
A single bolus treatment with eRFRP3 administered at a suprapharmacological 
dose will suppress secretion of LH stimulated by continuous administration of native 
GnRH. 
3.2.3.2 Specific objectives 
Determine whether 5 mg of eRFRP3, injected i.v. in a single bolus can suppress 
the pulsatile pattern of LH in winter anovulatory mares induced to secret LH by 
continuous administration of native GnRH. 
3.2.3.3 Animals and study location 
Six Quarter Horse mares ranging from 320-410 kg of body weight and 4-26 yr of 
age were maintained on pasture (Coastal Bermuda grass) at the Experiment Station and 
supplemented with a mixed grain concentrate (12% crude protein; Falls City Milling, 
Falls City, TX) to maintain body condition score between 5 and 6 on a scale of 1 to 9. 
Mares were confirmed as anovulatory by daily transrectal ultrasonography to monitor 
ovarian events, and analyses of serum progesterone concentrations for at least one 
month. For the mares to be considered anovulatory serum concentration of progesterone 
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was required to be lower than 1 ng/mL during this period with no ovarian follicles >30 
mm. Mares were assigned in a replicated Latin square design (Table 2) to receive saline 
or eRFRP3 (5 mg i.v) in saline in random order on consecutive days, with a 24 h 
washout period between treatment/sampling. Treatments were injected at Time 0 and 
ICS blood samples were collected at 5-min intervals for 3 h following the post 
harvesting procedure described in Exp. 2.  Samples were assayed for LH as in Exp. 1 
and 2 to assess the episodic pattern and mean concentrations of LH. 
 
 
 
 
Fig. 5. Time line for experiment relative to GnRH pump insertion and to sampling 
period. 
 
 
 
Table 2: Schedule for experiment relative to sampling period.  
Replicate Mare Day 1 Day2 
1 1 and 2 C-mare1/ RFRP3- mare2 RFRP3-mare1/ C-mare2 
2 3 and 4 RFRP3-mare3/ C-mare4 C-mare3/ RFRP3-mare4 
3 5 and 6 C-mare5/ RFRP3-mare6 RFRP3-mare5/ C-mare6 
    Treatments: C= saline; RFRP3= 5 mg of RFRP3. 
 
 
 
GnRH pump 
insertion 
d 0 d 5 d 6 
Catheterization Sampling: Saline or 5 mg 
of eRFRP3 
  
Washout period 
Sampling: Saline or 5 mg 
of eRFRP3 
  
// 
d 7 
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3.2.3.4 Hormone analysis 
 Hormone analysis for LH was the same as for experiment 1 and 2. Mean intra- 
and inter-assay CV were 10.8% (±2.5) and 10.3%, respectively. Concentrations of 
progesterone in serum were measured using a commercial single antibody kit 
(Diagnostic Products Corporation, Los Angeles, CA) for samples collected daily. All 
samples were analyzed for progesterone in a single assay with minimum detectable 
concentration of 0.1 ng/ml. 
3.2.3.5 Statistical Analysis 
Because of the inability to detect secretory episodes of LH using the 
methodology described in Exp.2, only mean concentrations of LH were statistically-
analyzed and analyses were performed as described in Exp.1. 
3.2.4 Experiment 4 
Determine the effects of a suprapharmacological dose of ovine RFRP3 (oRFRP3) 
on the secretion of LH in mares in the follicular phase. 
3.2.4.1 Hypothesis 
A single bolus dose of oRFRP3 administered at a suprapharmacological level 
will suppress secretion of LH. 
3.2.4.2 Specific objectives 
Determine the ability of 5 mg of oRFRP3, injected i.v. in a single bolus in the 
suppression of the mean concentration and pulsatile pattern of LH in mares during 
follicular phase of the estrous cycle. 
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3.2.4.3 Animals and study location 
 Six Quarter Horse mares ranging from 360-500kg of body weight and 3-15 yr of 
age were maintained on pasture (Coastal Bermuda grass) at the Experiment Station and 
supplemented with a mixed grain concentrate (12% crude protein; Falls City Milling, 
Falls City, TX) to maintain body condition score between 5 and 6 in a scale from 1 to 9. 
The day of ovulation and CL regression (Fig. 6) were the same as described on 3.2.1.3 
and 3.2.2.3. Mares were assigned in completely randomized design to receive saline 
(n=3) or oRFRP3(n=3) (10 µg/kg of BW delivered i.v, with the total dose ranging from 
3mg to 5mg depending on the size of the mare). Samples were collected from the ICS 
cannula at 5-min intervals for 3h. At 180 min, saline or oRFRP3 was injected and 
samples were collected for 3 more h following the same procedure for blood processing 
as described in Exp. 2 and 3. Samples were assayed for LH as in Exp. 1, 2, and 3 to 
determine mean concentrations of LH. 
 
 
 
Fig. 6.Time Line for experiment relative to day of ovulation and for experiment relative 
to sampling period. 
 
d0 d7 d8 d9 
Ovulation PGF2α Catheterization Sampling 
  
0 -180 min 
Sampling 
every 5 min 
185 – 360 
min 
Sampling 
every 5 min 
oRFRP3 Injection 
or Saline 
// 
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3.2.4.4 oRFRP3 sequence synthesis  
 The ovine sequence (NH2-Val-Pro-Asn-Leu-Pro-Gln-Arg-Phe-Amide), provided 
by Dr. Terry Nett, Colorado State University, was synthesized and chemically validated 
(High-performance liquid chromatography and Mass spectral analysis (95% of purity 
and 969 of molecular weight)) by United Biochemical Research, Inc. (Seattle, WA,US).  
3.2.4.5 Hormone analysis 
 The RIA for LH was the same as for experiment 1, 2, and 3. Mean intra- and 
inter-assay CV were 13.2 (±3.8) and 12.2%, respectively.  
3.2.4.6 Statistical Analysis 
Because of an inability to detect episodic release of LH in ICS samples from 
mares used in this experiment, only mean concentrations of LH were compared using the 
same procedure described in Exp.2 excluding the other variables not measured in this 
case.  
3.3 Results 
3.3.1 Experiment 1  
Figure 7 represents least-squares mean concentrations of LH for mares in each 
experimental group during the 7-day GnRH infusion (20 µg/h) period leading up to 
experimental treatments with RFRP3 or saline (control) on Day 7. Mean concentrations 
determined from single daily jugular samples did not differ among groups (P=0.99). 
Figure 8 shows mean concentration of LH during the 4-h intensive sampling period 
(samples collected every 15 min), pooled by hour, before and after onset of RFRP3 and 
saline (control) treatments. Since mean baseline concentrations of LH differed among 
38 
 
the 3 groups at the onset of sampling period, data are normalized as the percentage of 
time zero values. Mean concentrations of LH were not affected by treatment (P=0.99).  
 
 
 
Fig. 7. LSmean concentrations of LH (ng/mL ± SEM) in each experimental group during 
the 7-d GnRH infusion period before experimental treatments. 
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Fig. 8. Normalized mean concentration of LH (% of time zero) in saline (control) and 
eRFRP3-treated (500 and 1000 µg) mares pooled by hour from samples collected every 
15 min. 
 
 
 
3.3.2 Experiment 2 
Episodic secretion patterns of LH in 2 representative control and 2 representative 
eRFRP3-treated mares are shown in Fig. 9. Areas under the GnRH-induced LH curves 
for each treatment are shown in Fig. 10. Treatment with eRFRP3 (250 µg/h) every 10 
min for 4 h before GnRH challenge and continuing for 2 h after GnRH challenge had no 
effect on any variables measured, including mean concentration (P=0.35), frequency 
(P=0.23), amplitude (P=0.60), and duration (P=0.25) of LH secretory episodes, nor on 
areas under the GnRH-induced release of LH (P=0.31; Table 3).  
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Fig. 9. Pattern of secretion of LH for 2 representative control (left panels) and 2 
representative eRFRP3-treated mares (right panels). Mares were injected i.v. with either 
saline or 250 μg eRFRP3 every 10 min for 4 h beginning 60 min after the start of 
sampling.  
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Fig. 10. GnRH-induced release of LH in mares treated with GnRH (1 mg i.v.) at time 
365 min (represented as time 0) of intensive sampling. Samples were collected every 15 
min post GnRH-infusion for 2 h.  
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Table 3: LSmean (± SEM) concentrations of LH, frequencies, amplitudes, and durations 
of LH secretory episodes before (Period 1) and during (Period 2) treatment with saline or 
eRFRP3, and GnRH-induced release of LH. Saline or RFRP3 (250μg/injection) was 
injected at 10-min intervals for 4 h before GnRH treatment and continued for an 
additional 2 h after a bolus i.v. injection of 1mg GnRH. No effects of eRFRP3 were 
detected. 
 Treatments 
 Control eRFRP3 
Period* 1 2 1 2 
LH (ng/mL) 1.8 ± 1.2 1.9 ± 1.4 1.3  ± 0.5 1.3 ± 0.4 
Amplitude (ng/mL) 0.3 ± 0.02 0.3 ± 0.02 0.2 ± 0.03 0.2 ± 0.02 
Frequency 2.8 ± 0.5 5.3 ± 0.5 2.1 ± 0.5 4.0 ± 0.5 
Duration (min) 35. 2 ± 2.7 33.6 ± 2.1 40.4 ± 2.9 46.1 ± 2.2 
GnRH-induced 
release of LH (Area 
under the curve)** 
 
175.9±11.4 
 
192.6±10.6 
* Period 1 – before treatment; Period 2- after treatment 
** Arbitrary units 
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3.3.3 Experiment 3 
This experiment examined the ability of a very large dose of eRFRP3, 
administered as a single bolus i.v. injection, to suppress the episodic release of LH in the 
ICS of winter anovulatory mares infused continuously with GnRH (100 µg/h) for 7 d. 
The patterns of secretion of LH from 2 representative saline-treated control and 2 
eRFRP3-treated mares, respectively, are shown on Fig. 11. Overall least-squares mean 
concentrations of LH for both treatments are shown in Fig. 12. Treatment with eRFRP3 
had no effect on secretion of LH (P=0.66) in this experiment. 
 
 
 
 
Fig. 11. LH secretory pattern plotted using three-point rolling average of 5 min samples 
collected over 3-h for representative mares during the treatment and control period. 
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Fig. 12. Mean concentrations of LH in mares administered saline control or 5 mg 
eRFRP3 i.v. 
 
 
 
3.3.4 Experiment 4 
Because no effects of eRFRP3 were noted in Exp. 1-3, a final study was done 
utilizing an ovine RFRP3 as a positive control. Previously, the ovine homolog of the 
avian RFRP3 has been shown to suppress secretion of LH in sheep. However, treatment 
of follicular phase mares with oRFRP3 (10µg/kg of BW) as a single i.v. bolus injection 
failed to result in measurable decrease in mean concentrations of LH (P=0.58) in ICS 
plasma (Fig. 13). 
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Fig. 13. Mean concentrations of LH for mares in saline control (n=3) and oRFRP3 
(10µg/kg of BW; n=3) groups for 3 h before (Period 1) and 3 h after (Period 2) 
treatment. ICS concentrations of LH were determined in blood samples collected at 5-
min intervals. 
 
 
 
3.4 Discussion 
 The discovery and characterization of avian GnIH [14, 17, 24, 29, 30, 130, 131] 
and mammalian RFRP3 [17, 18, 19, 20, 135] has resulted in significant evidence to 
indicate that this peptide is able to suppress the secretion of LH and is involved in the 
control of reproductive seasonality in birds [131], and perhaps some mammals [18]. 
However, none of these studies were conducted in the mare, a species which is 
profoundly seasonal and in which seasonality has significant economic ramifications.   
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In the current studies, we set out to examine if RFRP3 could contribute to the 
mechanisms that control seasonality in the mare. Results indicate that neither eRFRP3 at 
any dose or manner tested, nor oRFRP3 as a large single dose, is able to suppress 
episodic release, mean concentration, or GnRH-induced release of LH in mares. Thus, 
our studies were unable to support the hypothesis that RFRP3 acts as an inhibitory signal 
that can suppress the secretion of LH through effects at the hypothalamic or pituitary 
gonadotrope level in the mare. 
In the first of four experiments, we used a model that compared the ability of 500 
and 1,000µg of eRFRP3 to suppress peripheral concentrations of LH during the luteal 
phase of mares treated continuously with GnRH. The continuous infusion of GnRH was 
utilized because previous studies in our lab [11] have shown that such treatments 
markedly increase the LH baseline and create a consistent pattern of high-frequency 
pulses. Thus, this eliminates the need to synchronize mares to a particular phase of the 
cycle and avoids the infrequent, long-duration episodes of LH release that are observed 
during the normal luteal phase [167, 168, 169, 170]. The latter would make it quite 
difficult to contrast RFRP3 effects in mares due to asynchronous occurrences of large 
episodes of LH. As shown in Figure 9, the eRFRP3 treatments did not suppress mean 
concentration of LH. Although, earlier studies have shown that intravenously-
administered RFRP3/GnIH is effective in suppressing circulating concentrations of LH 
in rats [35], in Syrian hamsters [20], and in male song sparrows [131]. Furthermore, 
RFRP3 suppressed secretion of LH in female rat pituitary cells cultured in the presence 
of GnRH [35]. 
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For the second experiment, we used mares in the follicular phase of estrous cycle 
and treated them with eRFRP3 every 10 min for 6 h (total dose of 9 mg of RFRP3). 
Treatment did not affect duration, frequency, or amplitude of LH release episodes or 
mean concentration measured in intensively-collected ICS sampled. The ICS 
cannulation technique was chosen for this experiment to facilitate detection of LH 
secretory episodes that otherwise cannot be detected in peripheral plasma [167]. Mares 
where challenged with 1 mg of GnRH after 360 min of intensive sampling in order to 
induce maximal release of LH from the anterior pituitary. The resulting increment in LH 
was similar to that observed previously when mares on the second or third day of the 
estrous cycle were treated intravenously with GnRH at a dose of 2µg/kg BW. Treatment 
with RFRP3 was ineffective in modifying GnRH-induced release of LH. As in a 
previous study, the concentration of LH in plasma never returned to baseline during the 
sampling period [69]. Earlier studies in ruminants have included male calves injected 
with RFRP3 (90µg) every 10 min for 1 h [33] and ovariectomized ewes given a loading 
dose of 50 μg followed by a continuous infusion of 200 μg for over 1 h [18]. Both 
studies indicated that RFRP3 suppressed pulsatile release of LH. However, when 
ovariectomized prepubertal gilts were given a loading dose of 1mg of RFRP3 and then 
treated with 40µg of RFRP3 [intracerebroventricular, i.c.v] every 5 min for 2 h, neither 
mean concentrations of LH nor the number or amplitude of LH pulses were altered 
[171]. Moreover, area under the curve was also calculated for the period before and after 
RFRP3 treatment and no statistical difference was observed for total LH release between 
periods. Experiments have also been conducted in rodents. When ovariectomized, 
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estradiol-replaced rats were treated i.c.v with RFRP3, no effects on the pattern of LH 
release were observed [32]. However, in another study with ovariectomized female rats, 
i.v. treatment with 1 or 10µg of RFRP3, in combination with either saline or GnRH, 
reduced peak LH at minute 5 after GnRH [144]. Furthermore, secretion of LH was 
inhibited in pituitary cell cultures of male quail [29], rat [35], chicken [146], and sheep 
[18] treated with RFRP3. Thus, effects of RFRP3 in mammalian species have been 
somewhat mixed. With respect to ruminant species, at least two other studies in sheep 
have been conducted without confirmation of significant RFRP3 effects [Drs. Terry 
Nett, Colorado State University and Dr. Alain Caraty, INRA, Nouzilly, France, personal 
communications]. 
In the third experiment reported herein, mares were confirmed anovulatory and 
were administered an Alzet osmotic pump delivering GnRH s.c at a rate of 100µg/h of 
for 7 d. Previous studies have shown repeatedly that continuous GnRH treatment 
stimulates the secretion of LH from the anterior pituitary during the non-breeding season 
[11, 172, 173, 174]. Treatment with a bolus injection of 5mg RFRP3 failed to affect 
mean concentrations of LH compared to saline controls in samples collected from the 
ICS. Unfortunately, the degree of stimulation of the LH baseline in this study was not 
adequate to allow reliable detection of the episodic release of LH in these mares. In rats 
treated with estradiol to induce the release of GnRH/LH, both 2.5 and 25 ng of RFRP3 
(i.c.v) suppressed activation of 70% of anteroventral periventricular GnRH cells [32]. 
However, the investigators were not able to demonstrate a significant decrease in plasma 
concentration of LH [32]. In cultured ovine pituitary cells treated with GnRH, oRFRP3, 
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or GnRH+oRFRP3, a dose dependent inhibition of LH was observed only when 
oRFRP3 was applied to cells in the presence of GnRH [18]. Similarly, a study conducted 
in photorefractory song sparrows showed that secretion of LH was attenuated more in 
the group treated with GnRH than in the group treated with GnRH plus 1,000µg of quail 
GnIH [131]. 
Finally, in the last experiment reported, we tested the hypothesis that mares in the 
follicular phase treated with an ovine sequence of RFRP3 (NH2-Val-Pro-Asn-Leu-Pro-
Gln-Arg-Phe-Amide) would exhibit suppression of LH release similar to that reported 
previously in ovariectomized ewes [18]. Thus, this experiment served as a positive 
control using a peptide sequence shown previously to have significant biological effects 
across multiple mammalian species [18, 33, 34, 35, 137].  It appears that the last 3 amino 
acids of all homologs are identical across species and confer biological activity to the 
molecule. For example, when white-crowed sparrows were castrated during their non-
breeding season, photostimulated, and injected with 500µg of quail GnIH, mean plasma 
concentrations of LH were significantly reduced within 3 min after injection [131], 
demonstrating the heterospecificity of this peptide. The dose of RFRP3 chosen for our 
experiment was 10µg/kg of BW, which is similar to that reported previously in studies 
where RFRP3 suppressed LH [18, 33]. Similar to Exp. 3, we were not able to measure 
the episodic release of LH in the pituitary venous effluent and only mean concentrations 
of LH were compared. Mares used in this experiment had relatively low baseline 
concentrations of LH that were not characterized by robust pulses. No effects of 
oRFRP3 were observed on mean concentration of LH in samples collected at 5-min 
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intervals from the ICS. The ovine sequence utilized in this experiment has been shown to 
be efficient in suppressing the pulsatile secretion pattern of LH as well as LH release 
from cultured ovine pituitary cells and in an in vivo experiment [18]. However, the 
preparation itself, obtained from Dr. Terry Nett, Colorado State University, was shown 
to have no effect on pulsatile release of LH in ewes. 
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CHAPTER IV 
CONCLUSION 
 
 
 
Results obtained in the four experiments described herein indicate that the equine 
hypothalamic-gonadotropic axis is not responsive to RFRP3 as shown previously in 
some other experiments with birds and mammals. Thus, we were not able to provide 
evidence of a contribution of RFRP3 to reproductive seasonality in the mare. Infusion of 
both eRFRP3 and oRFRP3 did not disrupt either the normal pattern of LH release, 
GnRH-induced release of LH, or mean concentration of LH as demonstrated to occur in 
earlier studies with other seasonal species. Therefore, results do not support a role for 
RFRP3 in regulating the reproductive neuroendocrine axis of the mare.  
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APPENDIX 
PROCEDURES 
 
 
 
Equine LH RIA 
References: 
Davis SL, Riechert LE, Niswender GD. Biol. Reprod. 4:415- (1971) 
Echternkamp SE, Bolt DJ, Hawk HW.  J. Anim. Sci. 42:893- (1976) 
Golter TD, Reeves JJ, O’Mary CC, Arimura A, Schally AV.  J. Anim. Sci. 37:123- 
(1973) 
Niswender GD, Riechert LE, Midgley AR, Nalbandov AV. Endocrinology 84:1166- 
(1969) 
Williams GL, Ray DE.  J. Anim. Sci. 50:906- (1980) 
1. Iodinated Product: Iodination grade eLH (AFP-5130A). 
2. Antibody: Anti-equine LH (AFP-240580). Dilution 1:125,000. 
3. Standards: Iodination grade eLH (AFP-5130A). Range 0.1 – 20.0 ng/ml. 
4. References: eLH added to equine serum 
5. RIA Procedure: 
 A. Day 1: Begin Assay 
  1. NSB – 500 μl of 1% PBS-EW (egg white). 
  2. 0 Std – 500 μl of 1% PBS-EW 
  3. Stds – 200 μl std + 300 μl of 1% PBS-EW. 
  4. Ref – 200 μl ref + 300 μl of 1% PBS-EW. 
  5. Unknown – 200 μl sample + 300 μl of 1% PBS-EW. 
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6. Pipette 200 μl of PBS-EDTA + 1:400 NRS without primary 
 antibody into     NSB tubes only. 
  7. Pipette 200 μl of anti-eLH (diluted in PBS-EDTA + 1:400 NRS) 
 into all tubes except NSB and TC tubes. 
  8. Pipette 100 μl 125I-eLH (20,000 cpm/100 μl diluted in 1% PBS-EW) 
  to all tubes. 
  9. Vortex tubes briefly and incubate for 24 h at 4°C. 
 B. Day 2: Add Second Antibody 
  1. Pipette 200 μl of Sheep-anti-rabbit gamma globulin (SARGG; 2nd 
  Ab) diluted in PBS-EDTA without NRS into all tubes except TC 
  tubes. 
  2. Vortex tubes briefly and incubate for 48-72 h at 4°C. 
   C. Day 4: Pour Off Assay 
  1. Add 3 ml ice cold PBS (0.01 M; pH 7.0) to all test tubes except TC 
  tubes. 
  2. Centrifuge tubes for 1 h at 4°C at 3600 rpm. 
  3. Decant supernatant. 
  4. Count radioactivity of each tube using a gamma counter 
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Progesterone RIA 
Single Antibody RIA Kit, Diagnostic Products Corporation, Los Angeles, CA 
References: 
 Jones EJ, Armstrong JD, Harvey RW. J. Anim. Sci. 69:1607 – (1991) 
 Diagnostic Products Corporation Coat-A-Count Progesterone Kit, Los  
 Angeles, CA 
Simpson, R.B., Armstrong, J.D. and Harvey, R.W. J. Anim. Sci. 70: 1478–
(1992). 
1. Iodinated Product: Iodination grade hP4. 
2. Antibody: Anti-human P4 coated tubes. 
3. Standards: Human serum with added P4. Range 0.1 – 20.0 ng/ml. 
4. Reference: Human standard preparation added to bovine serum. 
5. RIA Procedure: 
 A. Begin and complete assay 
  1. Pipette in non-coated polypropylene tubes 
    NSB – 100 μl of 0 Std 
  2. Pipette in antibody coated tubes 
   0 Std – 100 μl 
   Std – 100 μl 
   Ref – 100 μl 
   Unknowns – 100 μl 
  3. Pipette 1 ml of 125I –P4 provided in the kit to all tubes including two 
  Total Count non-coated polypropylene tubes. 
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  4. Vortex tubes briefly and incubate at room temperature for 3 h. 
  5. Pour off supernatant. 
  6. Count radioactivity of each tube using a gamma counter 
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